[go: up one dir, main page]

ATE319483T1 - Verfahren und zusammensetzungen zur selektiven modikation von nukleinsäuren - Google Patents

Verfahren und zusammensetzungen zur selektiven modikation von nukleinsäuren

Info

Publication number
ATE319483T1
ATE319483T1 AT01107780T AT01107780T ATE319483T1 AT E319483 T1 ATE319483 T1 AT E319483T1 AT 01107780 T AT01107780 T AT 01107780T AT 01107780 T AT01107780 T AT 01107780T AT E319483 T1 ATE319483 T1 AT E319483T1
Authority
AT
Austria
Prior art keywords
compositions
nucleic acids
selective modification
blood
compsn
Prior art date
Application number
AT01107780T
Other languages
English (en)
Inventor
Edward I Budowsky
Samuel K Ackerman
Original Assignee
Panacos Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacos Pharmaceuticals Inc filed Critical Panacos Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE319483T1 publication Critical patent/ATE319483T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C07D203/12—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10161—Methods of inactivation or attenuation
    • C12N2730/10163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32461—Methods of inactivation or attenuation
    • C12N2770/32463—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18161—Methods of inactivation or attenuation
    • C12N2795/18163—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
AT01107780T 1995-08-29 1996-08-29 Verfahren und zusammensetzungen zur selektiven modikation von nukleinsäuren ATE319483T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/521,245 US6114108A (en) 1995-08-29 1995-08-29 Methods and compositions for the selective modification of viral nucleic acids

Publications (1)

Publication Number Publication Date
ATE319483T1 true ATE319483T1 (de) 2006-03-15

Family

ID=24075988

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96929846T ATE217144T1 (de) 1995-08-29 1996-08-29 Verfahren und zusammensetzungen zur selektiven modifikation von nukleinsaeuren
AT01107780T ATE319483T1 (de) 1995-08-29 1996-08-29 Verfahren und zusammensetzungen zur selektiven modikation von nukleinsäuren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT96929846T ATE217144T1 (de) 1995-08-29 1996-08-29 Verfahren und zusammensetzungen zur selektiven modifikation von nukleinsaeuren

Country Status (18)

Country Link
US (1) US6114108A (de)
EP (2) EP1129728B1 (de)
JP (2) JP2001520635A (de)
KR (1) KR100486765B1 (de)
AT (2) ATE217144T1 (de)
AU (1) AU694892B2 (de)
BR (1) BR9610306A (de)
CA (1) CA2230671A1 (de)
DE (2) DE69621161T2 (de)
DK (1) DK0915648T3 (de)
ES (1) ES2173314T3 (de)
HK (1) HK1042254A1 (de)
IL (1) IL123467A0 (de)
NO (1) NO980881L (de)
NZ (1) NZ316787A (de)
PL (1) PL187759B1 (de)
PT (1) PT915648E (de)
WO (1) WO1997007674A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691132A (en) 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
US6177441B1 (en) 1995-06-05 2001-01-23 Cerus Corporation Treating red blood cell solutions with anti-viral agents
US20040048235A1 (en) * 1995-08-29 2004-03-11 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US20040053208A1 (en) * 1995-08-29 2004-03-18 V. I. TECHNOLOGIES, Inc. Methods to selectively inactivate parasites in biological compositions
US6136586A (en) * 1995-08-29 2000-10-24 Vi Technologies, Inc. Methods for the selective modification of viral nucleic acids
DE19633684A1 (de) * 1996-08-12 1998-02-19 Dirk Dipl Ing Vollenbroich Verfahren zur Inaktivierung von lipidumhüllten Viren
US6093725A (en) * 1997-01-06 2000-07-25 Cerus Corporation Frangible compounds for pathogen inactivation
US6514987B1 (en) 1997-01-06 2003-02-04 Cerus Corporation Frangible compounds for pathogen inactivation
US5891705A (en) * 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
US6093564A (en) 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6352695B1 (en) * 1997-10-03 2002-03-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US7569342B2 (en) 1997-12-10 2009-08-04 Sierra Molecular Corp. Removal of molecular assay interferences
CA2317603A1 (en) 1998-01-06 1999-07-15 Cerus Corporation Methods for quenching pathogen inactivators in biological materials
US6369048B1 (en) 1998-01-12 2002-04-09 V.I. Technologies, Inc. Methods and compositions for inactivating viruses
AU4435399A (en) 1998-06-11 1999-12-30 Cerus Corporation Inhibiting proliferation of arterial smooth muscle cells
DE19827750C1 (de) 1998-06-22 1999-07-29 Centeon Pharma Gmbh Verfahren zum Abtrennen von HIV aus einer Flüssigkeit
US6099734A (en) * 1998-07-08 2000-08-08 Baxter International Inc. Apparatus, membranes and methods for removing organic compounds from a biological fluid
US6908553B1 (en) 1998-07-08 2005-06-21 Baxter International Inc. Composite membrane with particulate matter substantially immobilized therein
US7049110B2 (en) 1998-07-21 2006-05-23 Gambro, Inc. Inactivation of West Nile virus and malaria using photosensitizers
US7498156B2 (en) 1998-07-21 2009-03-03 Caridianbct Biotechnologies, Llc Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
DE19836559A1 (de) 1998-08-12 2000-03-23 Antigen Gmbh Gefäß zur Entnahme von Blut
US6617100B2 (en) * 1998-09-25 2003-09-09 V.I. Technologies, Inc. Solid phase quenching systems
US6403359B1 (en) 1998-09-25 2002-06-11 V. I. TECHNOLOGIES, Inc. Solid phase quenching systems
EP1115889A4 (de) * 1998-09-25 2003-02-05 Vi Technologies Inc Methoden zur selektiven inaktivierung von viren in biologischen zusammensetzungen
US6150109A (en) 1999-01-25 2000-11-21 V. I. TECHNOLOGIES, Inc. Lipophilic quenching of viral inactivating agents
WO2000066175A2 (en) 1999-04-30 2000-11-09 Slil Biomedical Corporation Conjugates as therapies for cancer and prostate diseases
US7094378B1 (en) 2000-06-15 2006-08-22 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US7220747B2 (en) 1999-07-20 2007-05-22 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
AU2002243363A1 (en) * 2000-11-06 2002-07-24 V.I. Technologies, Inc. Use of aziridino-compounds in the treatment of immune dysfunctions
US6602718B1 (en) 2000-11-08 2003-08-05 Becton, Dickinson And Company Method and device for collecting and stabilizing a biological sample
US20020131958A1 (en) * 2001-01-22 2002-09-19 John Chapman Method for purifying a biological composition
US6635679B2 (en) 2001-05-14 2003-10-21 Akzo Nobel N.V. Methods and compositions for inactivating viruses
WO2002092806A1 (en) * 2001-05-15 2002-11-21 V.I. Technologies, Inc. Apparatus for the inactivation of pathogens in protein-containingfluids
EP1436246A1 (de) 2001-10-16 2004-07-14 SLIL Biomedical Corporation Oligoamin-verbindungen und ihre derivate für die krebstherapie
JP2005517023A (ja) * 2001-11-06 2005-06-09 ヴイ．アイ．テクノロジーズ，インコーポレーテッド アジリジン化合物の治療的使用
WO2003057129A1 (fr) 2001-12-28 2003-07-17 Terumo Kabushiki Kaisha Systeme de sac sanguin et procede d'inactivation de micro-organismes pathogenes
US20050074743A1 (en) * 2003-10-06 2005-04-07 Purmal Andrei A. Method and composition for treating a biological sample
DK1838355T3 (da) 2004-10-29 2013-10-28 Cerus Corp Forbedrede quenching-fremgangsmåder til erytrocyt-inaktiveringsfremgangsmåde
BRPI0911176B8 (pt) 2008-04-09 2021-05-25 Cerus Corp método de tratar uma composição de célula vermelha sanguínea, composição de célula vermelha sanguínea, e método de reduzir a desidratação em uma composição de célula vermelha sanguínea
MX363044B (es) 2012-06-01 2019-03-06 Boehringer Ingelheim Vetmedica Gmbh Vacuna de virus de schmallenberg (sbv), metodos de produccion y sus usos.
KR20180091824A (ko) 2015-11-01 2018-08-16 글리코백, 엘엘씨 바이러스 비함유 세포주 및 이를 획득하기 위한 방법
EP3454895B1 (de) 2016-05-10 2024-03-27 Najit Technologies, Inc. Anorganische polyatomare oxyanionen zum schutz gegen antigene beschädigung während der pathogeninaktivierung zur impfstoffherstellung
KR102198877B1 (ko) 2019-07-16 2021-01-05 정소영 블루 라이트 차단 필터
CN113322252A (zh) * 2020-12-28 2021-08-31 广州凯普医药科技有限公司 一种拭子样本保存液

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492289A (en) * 1966-06-13 1970-01-27 Dow Chemical Co Polymers of alkylenimines
US4036952A (en) * 1973-02-24 1977-07-19 Bayer Aktiengesellschaft Ethyleneimine inactivated microorganisms
US4058599A (en) * 1973-02-24 1977-11-15 Bayer Aktiengesellschaft Ethyleneimine inactivated organisms
RU594771C (ru) * 1973-05-07 1993-07-07 Всесоюзный научно-исследовательский ящурный институт Средство дл инактивации вирусов при изготовлении противовирусных препаратов
US4841023A (en) * 1986-06-25 1989-06-20 New York Blood Center, Inc. Inactivation of viruses in labile protein-containing compositions using fatty acids
US5000951A (en) * 1987-03-09 1991-03-19 Diamond Scientific Company Multivalent canine distemper virus vaccine
US5055485A (en) * 1988-12-02 1991-10-08 New York Blood Center, Inc. Inactivation of viruses in cell- and protein-containing compositions using aryl diol epoxides
RU1768636C (ru) * 1989-08-16 1992-10-15 Всесоюзный научно-исследовательский ветеринарный институт птицеводства Способ получени антигена вируса болезни Гамборо
US5120649A (en) * 1990-05-15 1992-06-09 New York Blood Center, Inc. Photodynamic inactivation of viruses in blood cell-containing compositions
US5232844A (en) * 1990-05-15 1993-08-03 New York Blood Center Photodynamic inactivation of viruses in cell-containing compositions
US5565205A (en) * 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
EP0500893A4 (en) * 1990-09-04 1993-03-10 Edward Shanbrom Preservation of blood, tissues and biological fluids
GB9108682D0 (en) * 1991-04-23 1991-06-12 Wellcome Found Production of vaccines
FR2679253B1 (fr) * 1991-07-15 1994-09-02 Pasteur Institut Proteines de resistance a la cycloheximide. utilisation comme marqueur de selection par exemple pour controler le transfert d'acides nucleiques.
EP0612532A3 (de) * 1993-02-26 1998-02-04 Solvay Animal Health, Inc. Hunde Coronavirus Impfstoff aus einem Katzen-enterischen Coronavirus
AU722811B2 (en) * 1995-06-07 2000-08-10 Cerus Corporation Treating red blood cell solutions with anti-viral agents

Also Published As

Publication number Publication date
AU694892B2 (en) 1998-07-30
ATE217144T1 (de) 2002-05-15
PL187759B1 (pl) 2004-10-29
NZ316787A (en) 1999-11-29
KR19990044303A (ko) 1999-06-25
EP1129728A1 (de) 2001-09-05
EP1129728B1 (de) 2006-03-08
NO980881L (no) 1998-04-27
DE69621161D1 (de) 2002-06-13
US6114108A (en) 2000-09-05
DE69621161T2 (de) 2002-11-21
KR100486765B1 (ko) 2005-09-02
HK1042254A1 (zh) 2002-08-09
IL123467A0 (en) 1998-09-24
EP0915648A1 (de) 1999-05-19
DE69635871D1 (de) 2006-05-04
EP0915648B1 (de) 2002-05-08
ES2173314T3 (es) 2002-10-16
JP2003176238A (ja) 2003-06-24
BR9610306A (pt) 1999-07-06
DK0915648T3 (da) 2002-08-26
PL325338A1 (en) 1998-07-20
DE69635871T2 (de) 2007-05-24
AU6909996A (en) 1997-03-19
WO1997007674A1 (en) 1997-03-06
PT915648E (pt) 2002-09-30
JP2001520635A (ja) 2001-10-30
NO980881D0 (no) 1998-02-27
CA2230671A1 (en) 1997-03-06
EP0915648A4 (de) 1999-05-19

Similar Documents

Publication Publication Date Title
DE69621161D1 (de) Verfahren und zusammensetzungen zur selektiven modifikation von nukleinsaeuren
ATE544466T1 (de) Verwendung von cpg oligonukleotide zur behandlung von hepatitis c virus infektion
ATE194921T1 (de) Verfahren zur inaktivierung von viren
DE69718612D1 (de) Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung
DE3789158D1 (de) Verfahren zur Sterilisation und Vorrichtung dafür.
DE69637181D1 (de) Vorrichtung zur inaktivierung von viralen kontaminationen in blutprodukten
DE69739758D1 (de) Vakzine zur behandlung von lymphomen und leukämie
DE69535758D1 (de) Lipid-analoge zur behandlung von viralen infektionen
DE69114653D1 (de) Sterilisierendes Gemisch und Verfahren zur Sterilisation.
DE69936285D1 (de) INDOLOi2,1-BöQUINAZOLIN-6,12-DIONE ANTIMALARIA DERIVATE UND METHODEN ZUR BEHANDLUNG VON MALARIA
DE69631381T2 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
DE3864984D1 (de) Verfahren und einrichtung zur sterilisation des zerstaeubers und/oder der luftzufuhr von medizinischen instrumenten, insbesondere von zahnaerztlichen instrumenten.
DE69922364D1 (de) Verfahren zur immunisierung und behandlung von h. pylori infektion
DE10075036I2 (de) Impfstoff und Diagnostikum f}r den Schweine-Cholera-Virus.
DE69111457D1 (de) Katheter und vorrichtung zur behandlung, insbesondere von lungenembolien.
DK0684842T3 (da) Præparat til behandling af tumorer og immunisering af organismer over for tumorer
ATE255594T1 (de) Hepatitis b inhibitoren
DE3777022D1 (de) Verfahren und praeparat zur inaktivierung von viren.
DE69231465D1 (de) Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
DE69637325D1 (de) Methode für die behandlung einer hepatitisvirusinfektion
DE68908118D1 (de) Verfahren zur herstellung von trockenem acetaldehyd und damit hergestelltes produkt.
JPH07233080A (ja) ｖｉｒｕｓをＡＩＤＳ治療に応用する方法
ATE98131T1 (de) Verfahren zur herstellung virusfreier naturstoffe.
ATE56878T1 (de) Verfahren und zusammensetzung zur vorbeugung und behandlung von virus-infektionen.
DE58902466D1 (de) Acyl-carnitin zur behandlung und zur verhuetung von virusinfektionen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties